The stock of Pasithea Therapeutics Corp (KTTA) has gone down by -38.57% for the week, with a -21.10% drop in the past month and a -54.97% drop in the past quarter. The volatility ratio for the week is 51.83%, and the volatility levels for the past 30 days are 25.83% for KTTA. The simple moving average for the last 20 days is -39.69% for KTTA stock, with a simple moving average of -71.24% for the last 200 days.
Is It Worth Investing in Pasithea Therapeutics Corp (NASDAQ: KTTA) Right Now?
The 36-month beta value for KTTA is also noteworthy at 0.50. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KTTA is 2.39M, and at present, short sellers hold a 17.45% of that float. The average trading volume of KTTA on May 09, 2025 was 5.54M shares.
KTTA) stock’s latest price update
Pasithea Therapeutics Corp (NASDAQ: KTTA)’s stock price has decreased by -10.42 compared to its previous closing price of 0.96. However, the company has seen a -38.57% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-07 that Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.
KTTA Trading at -33.41% from the 50-Day Moving Average
After a stumble in the market that brought KTTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.82% of loss for the given period.
Volatility was left at 25.83%, however, over the last 30 days, the volatility rate increased by 51.83%, as shares sank -46.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.58% lower at present.
During the last 5 trading sessions, KTTA fell by -38.64%, which changed the moving average for the period of 200-days by -85.16% in comparison to the 20-day moving average, which settled at $1.4260. In addition, Pasithea Therapeutics Corp saw -72.70% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTTA
The total capital return value is set at -0.95. Equity return is now at value -72.83, with -65.93 for asset returns.
Currently, EBITDA for the company is -13.26 million with net debt to EBITDA at 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.
Conclusion
In summary, Pasithea Therapeutics Corp (KTTA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
